Literature DB >> 10949925

Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma.

Y I Lee1, S Lee, G C Das, U S Park, S M Park, Y I Lee1.   

Abstract

Aflatoxin B1 (AFB1) induced mutation of the p53 gene at codon 249 (p53mt249) is critical during the formation of hepatocellular carcinoma (HCC) following hepatitis B virus (HBV) infection. p53mt249 markedly increases insulin-like growth factor II (IGF-II) transcription largely from promoter 4, accumulating the fetal form of IGF-II. Modulation of the transcription factor binding to IGF-II P4 by wild-type p53 and p53mt249 was identified. Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein (Sp1 or TBP) and protein-protein (Sp1 and TBP) interactions. p53mt249 stimulates transcription factor Sp1 phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not. Transfection of hepatocytes with p53mt249 impaired induction of apoptosis by the HBV-X protein and TNF-alpha. Therefore, the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes. These results explain the molecular basis for the genesis of HCC by p53mt249 which was found to be induced by a potent mutagen, AFB1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10949925     DOI: 10.1038/sj.onc.1203694

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.

Authors:  Xin-Juan Kong; Yu-Hu Song; Ju-Sheng Lin; Huan-Jun Huang; Nan-Xia Wang; Nan-Zhi Liu; Bin Li; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.

Authors:  Xing-Hua Huang; Lu-Hong Sun; Dong-Dong Lu; Yan Sun; Li-Jie Ma; Xi-Ran Zhang; Jian Huang; Long Yu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 4.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

5.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 6.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

7.  Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.

Authors:  Celia A Kanashiro; Andrew V Schally; Kate Groot; Patricia Armatis; Andrea L F Bernardino; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

Review 8.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 9.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

10.  Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.

Authors:  George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.